Modulation of MDR/MRP by wild-type and mutant p53.
作者信息
Bähr O, Wick W, Weller M
出版信息
J Clin Invest. 2001 Mar;107(5):643-6. doi: 10.1172/JCI12415.
Abstract
摘要
相似文献
1
Modulation of MDR/MRP by wild-type and mutant p53.野生型和突变型p53对多药耐药/多药耐药相关蛋白的调控
J Clin Invest. 2001 Mar;107(5):643-6. doi: 10.1172/JCI12415.
2
3
4
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.化学增敏剂的双刃剑：丙磺舒这种多药耐药蛋白（MRP）抑制剂会增加白血病细胞中的MRP
Biochem Biophys Res Commun. 2001 Apr 27;283(1):64-71. doi: 10.1006/bbrc.2001.4746.
5
6
[Multidrug resistance protein (MRP)].
Nihon Rinsho. 1997 May;55(5):1077-82.
7
[Multidrug resistance mechanisms in cell line HL-60/VCR].[细胞系HL-60/VCR中的多药耐药机制]
Ai Zheng. 2002 Dec;21(12):1310-3.
8
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.舒尼替尼使过表达ABCG2的细胞对传统化疗药物敏感，这与抑制ABCG2的功能有关。
Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.
9
Drug retention, efflux, and resistance in tumor cells.肿瘤细胞中的药物滞留、外排与耐药性。
Cytometry. 1997 Dec 1;29(4):279-85.
10
Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug-resistant human lung cancer cells.多药耐药的人肺癌细胞中，MDR1和MRP反义RNA的共转染消除了耐药性。
Anticancer Res. 1998 Jul-Aug;18(4C):3073-6.
引用本文的文献
1
Advancements in -Based Anti-Tumor Gene Therapy Research.基于 的抗肿瘤基因治疗研究进展。
Molecules. 2024 Nov 11;29(22):5315. doi: 10.3390/molecules29225315.
2
Role of SIRT1 in Chemoresistant Leukemia.SIRT1 在化疗耐药性白血病中的作用。
Int J Mol Sci. 2023 Sep 23;24(19):14470. doi: 10.3390/ijms241914470.
3
Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.化疗和放疗耐药的分子机制及其对癌症治疗的潜在影响。
MedComm (2020). 2021 Jun 10;2(3):315-340. doi: 10.1002/mco2.55. eCollection 2021 Sep.
4
Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?癌症中的糖基化：多药耐药性与上皮-间质转化之间的相互作用？
Front Oncol. 2016 Jun 22;6:158. doi: 10.3389/fonc.2016.00158. eCollection 2016.
5
Regulation of MAPKs Signaling Contributes to the Growth Inhibition of 1,7-Dihydroxy-3,4-dimethoxyxanthone on Multidrug Resistance A549/Taxol Cells.丝裂原活化蛋白激酶（MAPKs）信号通路的调控有助于1,7 - 二羟基 - 3,4 - 二甲氧基呫吨酮对多药耐药A549/Taxol细胞的生长抑制作用。
Evid Based Complement Alternat Med. 2016;2016:2018704. doi: 10.1155/2016/2018704. Epub 2016 Jun 15.
6
A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.需要临界剂量的阿霉素来改变获得多药耐药性的MCF-7细胞中的基因表达谱。
PLoS One. 2015 Jan 30;10(1):e0116747. doi: 10.1371/journal.pone.0116747. eCollection 2015.
7
A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.具有细胞质 p53（突变）的顺铂耐药头颈部癌细胞系表现出三磷酸腺苷结合盒转运体的上调和高谷胱甘肽水平。
J Cancer Res Clin Oncol. 2014 Oct;140(10):1689-704. doi: 10.1007/s00432-014-1727-y. Epub 2014 Jun 10.
8
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.携带p53基因的纳米颗粒可靶向包括癌症干细胞在内的肿瘤，使胶质母细胞瘤对化疗敏感并提高生存率。
ACS Nano. 2014 Jun 24;8(6):5494-514. doi: 10.1021/nn5014484. Epub 2014 May 15.
9
Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.热休克蛋白 27（Hsp27）的强制表达逆转了阿霉素耐药人乳腺癌细胞中 P-糖蛋白（ABCB1）介导的药物外排和多药耐药基因 1（MDR1）的表达。
J Biol Chem. 2011 Sep 23;286(38):33289-300. doi: 10.1074/jbc.M111.249102. Epub 2011 Jul 22.
10
Evaluation of 64Cu-labeled acridinium cation: a PET radiotracer targeting tumor mitochondria.评估 64Cu 标记的吖啶鎓阳离子：一种针对肿瘤线粒体的 PET 放射性示踪剂。
Bioconjug Chem. 2011 Apr 20;22(4):700-8. doi: 10.1021/bc100458p. Epub 2011 Mar 17.
本文引用的文献
1
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.恶性胶质瘤中存在一种组成性、维拉帕米敏感、非P-糖蛋白多药耐药表型的证据，该表型在体内不受放化疗影响。
Acta Neuropathol. 2000 May;99(5):555-62. doi: 10.1007/s004010051160.
2
Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.p53对人前列腺癌细胞中多药耐药蛋白MRP1表达的调控
J Clin Invest. 2000 May;105(9):1261-7. doi: 10.1172/JCI9290.
3
Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: reversal of resistance by cyclosporin A and hyperthermia.
Biochem Pharmacol. 1999 Jul 15;58(2):291-302. doi: 10.1016/s0006-2952(99)00094-5.
4
Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP.非甾体抗炎药对人胶质瘤细胞药物细胞毒性的选择性增强作用：COX-1和多药耐药相关蛋白的作用
Biochem Biophys Res Commun. 1999 Jun 16;259(3):600-5. doi: 10.1006/bbrc.1999.0825.
5
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.野生型p53对多药耐药相关蛋白（MRP）基因表达的转录抑制作用。
Cancer Res. 1998 Dec 15;58(24):5762-9.
6
Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.预测人类恶性胶质瘤细胞中的化疗耐药性：分子遗传学分析的作用
Int J Cancer. 1998 Dec 18;79(6):640-4. doi: 10.1002/(sici)1097-0215(19981218)79:6<640::aid-ijc15>3.0.co;2-z.
7
Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?地塞米松介导的对药物细胞毒性的保护作用：与p21WAF1/CIP1蛋白积累有关？
Oncogene. 1998 Sep 24;17(12):1567-75. doi: 10.1038/sj.onc.1202071.
8
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.人恶性胶质瘤的化学敏感性：p53基因转移的调节作用
J Neurooncol. 1998 Aug;39(1):19-32. doi: 10.1023/a:1005910323338.
9
'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.肿瘤衍生的突变型p53的“功能获得”表型需要寡聚化/非序列特异性核酸结合结构域。
Oncogene. 1998 Jun 18;16(24):3169-76. doi: 10.1038/sj.onc.1201857.
10
Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin.抗癌药物柔红霉素通过野生型p53介导诱导大鼠mdr1b表达。
J Biol Chem. 1998 Jun 19;273(25):15387-94. doi: 10.1074/jbc.273.25.15387.
Zotero 插件